Actively Recruiting
Phase 1 Study of 111In-XYIMSR-01 with SPECTCT Imaging in Adults with Metastatic Clear Cell Kidney Cancer
Led by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Updated on 2026-07-21
6
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating an investigational radiotracer called 111In-XYIMSR-01 to see if it helps detect clear cell renal cell carcinoma tissue during a SPECT-CT scan. The trial focuses on adults with metastatic clear cell renal cell carcinoma, aiming to assess the safety and imaging effectiveness of this radiotracer as part of a first-in-human Phase 1 study. Participants will receive a dose of 10.51 mCi of 111In-XYIMSR-01 delivered through an intravenous catheter. After dosing, they will undergo SPECTCT imaging to assess the biodistribution, radiation dosimetry, and total radioactivity concentration of the radiotracer in plasma. The study includes one group where all participants receive this investigational drug and are imaged accordingly. During the study, participants will be monitored from enrollment to one week after treatment. Researchers will track adverse events and evaluate the number of lesions detected through imaging. Clinical laboratory tests and imaging of disease sites will be reviewed to ensure safety and gather detailed data on the radiotracers behavior in the body.
CONDITIONS
Brief Title
Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell
Research Team
Y
Yasser Ged, MBBS
J
Jasmine Brooks
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
